Akebia TherapeuticsSTU:AX9 +1.24%49 PS Ratio is 1.44 as of Jul. 03, 2026, which is 18% below its 10-year median of 1.75. GuruFocus rates STU:AX9 with a GF Score™ of 49/100 and a GF Value™ of €1.11 (Fairly Valued). The stock has 5 warning signs investors should review. Among 950 Drug Manufacturers companies, Akebia Therapeutics ranks better than 66.53% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Akebia Therapeutics's share price is €1.065.
Akebia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.74. Hence, Akebia Therapeutics's PS Ratio for today is 1.44.
The historical rank and industry rank for Akebia Therapeutics's PS Ratio or its related term are showing as below:
STU:AX9'
s PS Ratio Range Over the Past 10 Years
Min: 0.16 Med: 1.75 Max: 263.75
Current: 1.43
During the past 13 years, Akebia Therapeutics's highest PS Ratio was 263.75. The lowest was 0.16. And the median was 1.75.
STU:AX9's PS Ratio is ranked better than 66.53% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs STU:AX9: 1.43
Akebia Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Akebia Therapeutics was 3.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -16.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -16.20% per year.
During the past 13 years, Akebia Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 310.20% per year. The lowest was -29.10% per year. And the median was -17.30% per year.
Back to Basics: PS Ratio
Akebia Therapeutics (STU:AX9) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Akebia Therapeutics PS Ratio Related Terms
Akebia Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Akebia Therapeutics's Share Price of today is €1.065. Akebia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Akebia Therapeutics (STU:AX9) has a PS Ratio of 1.44 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Akebia Therapeutics and its competitors. This is 18% below median its historical median of 1.75. Over the past decade, Akebia Therapeutics' PS Ratio has ranged from 0.16 to 263.75. According to the industry distribution chart, Akebia Therapeutics ranks #318 out of 950 companies in the Drug Manufacturers industry, placing it in the top 33.5%.
Is Akebia Therapeutics' PS Ratio too high?
Akebia Therapeutics' current PS Ratio of 1.44 is 18% below median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 263.75. The Drug Manufacturers industry median PS Ratio is 2.32. Akebia Therapeutics' value of 1.44 is 37.8% below this industry median. Based on the distribution chart, Akebia Therapeutics ranks #318 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' PS Ratio compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #318 out of 950 companies for PS Ratio. This puts Akebia Therapeutics in the upper half of its industry. The industry median PS Ratio is 2.32. Akebia Therapeutics' value of 1.44 is 37.8% below this benchmark. Historically, Akebia Therapeutics' own PS Ratio has ranged from 0.16 to 263.75 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 2.32, Akebia Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current PS Ratio of 1.44 is 37.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current PS Ratio is 1.44, which is 18% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.11, compared to a current price of €1.07 — trading 4.1% below its estimated fair value. The current PS Ratio is 1.44, which is 18% below median its 10-year median of 1.75 and 37.8% below the Drug Manufacturers industry median of 2.32. Akebia Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current PS Ratio is 1.44 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €1.07 is trading 4.1% below its estimated GF Value™ of €1.11.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for STU:AX9:
PS Ratio: 1.44 (18% below median its 10-year median of 1.75)
GF Value™: €1.11 vs. price of €1.07 (4.1% below fair value)
Industry Position: 37.8% below the Drug Manufacturers median (#318 of 950)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
49GF Score
Get the complete analysis for STU:AX9
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
